'Humanized' mice enable malaria research breakthrough

September 10, 2012
This image shows a maturing Plasmodium falciparum liver stage parasite in the liver of the human liver-chimeric FRGTM KO. Membranes of the developing merozoites are shown in red, DNA in blue, and the human hepatocytes within the liver-chimeric FRGTM KO mouse are shown in green. Credit: Seattle Biomedical Research Institute

A novel human liver-chimeric mouse model developed at Oregon Health & Science University and Yecuris Corporation has made possible a research breakthrough at Seattle Biomedical Research Institute that will greatly accelerate studies of the most lethal forms of human malaria.

The study findings are published online in the Journal of Clinical Investigation. Study photos were selected to appear in "Scientific Show Stoppers" on the JCI blog.

Plasmodium falciparum, one of two human-specific malaria parasites, is a global health crisis, causing more than 216 million new infections annually and resulting in an estimated 655,000 deaths, according to the World Health Organization.

Sporozoites, the infectious form of the parasite, are spread to people through the bites of infected mosquitos and multiply in the human liver during the initial stages of infection. There, they undergo liver stage development, culminating in the formation and release of tens of thousands of merozoites, the parasitic phase of development that infects red blood cells.

Until now, there have been few data on human malaria liver stage biology due to the lack of a viable small animal model and because liver stage P. falciparum does not grow well in a dish. Consequently, most research and therapeutics to date have targeted the human blood stage of P. falciparum's development because it replicates well in culture.

This image shows a section of a mature Plasmodium falciparum liver stage parasite in the liver of the human liver-chimeric FRGTM KO mouse. Individual merozoites are surrounded by a plasma membrane (red), and contain a single nucleus (blue) and a single apicoplast (green). Credit: Seattle Biomedical Research Institute

The liver-to-blood stage of P. falciparum is the focus of this research because the parasite is virtually harmless, causing no disease symptoms, prior to its transition to the blood stage.

In this study, researchers at Seattle Biomedical Research Institute, Yecuris Corporation, Oregon Health & Science University and The Rockefeller University have demonstrated that a complete liver-to-blood stage infection of P. falciparum is possible using a unique immunocompromised engrafted with human liver-chimeric cells.

The mouse model, termed the FRGTM KO mouse, was developed by paper co-author and internationally accomplished stem cell researcher Markus Grompe, M.D., in the Papé Family Pediatric Research Institute, a research arm of Oregon Health & Science University Doernbecher Children's Hospital.

In 2007 the technology was licensed to Yecuris Corporation, a biotechnology company that now produces the model and human hepatocytes on a commercial scale. As a result of this work, the FRGTM KO mouse now will be used to study new drug interventions, parasite attenuation and innate immune responses to P. falciparum liver stage infection.

The scientists also report that through the infection of the FRGTM KO mouse model, they were able to observe a previously unknown expression of proteins in liver stage development in humans that may be exploited for intervention. Equally important, they say, the FRGTM KO mouse could well provide unique opportunities for the study of another severe form of human malaria, Plasmodium vivax.

"These breakthroughs are remarkable and highlight OHSU and Yecuris' contributions to local biotechnology and research breakthroughs globally. The next generation mouse model we're developing will have a human immune system that will allow us to test not just drugs, but vaccines, which has never been done for parasitic diseases," said Grompe, Ray Hickey Chair and Director of the Papé Family Pediatric Research Institute, OHSU Doernbecher Children's Hospital; and professor of pediatrics, and molecular and medical genetics, OHSU School of Medicine.

Grompe founded Yecuris Corporation in 2007 and is a shareholder. John Bial, who joined Yecuris in 2009, is president and chief executive officer.

"The extensive collaborative relationships and risk-taking involved in planning and executing this research is a testament to the tireless dedication of these teams to solving one of the globe's oldest killers. It also highlights how private and public funding can come together effectively to address critical challenges in global health," said Bial.

"This first demonstration of the newly developed dual humanized FRGTM KO system is a good introduction to the kinds of translational medicine benefits that we can expect to see from these technologies. We anticipate that the next frontier for these systems will be as platforms for human vaccine development and validation, which may very likely first be tested in the area of ," Bial explained.

Explore further: Malaria vaccination strategy provides model for superior protection

More information: "Complete Plasmodium falciparum liver stage development in liver-chimeric mice," Journal of Clinical Investigation, 2012.

Related Stories

Malaria vaccination strategy provides model for superior protection

June 15, 2011
Malaria is a devastating disease caused by the Plasmodium parasite which is transmitted to humans by infected mosquitoes. Hundreds of millions of new cases of malaria are reported each year, and there are more than 750,000 ...

Improving human immunity to malaria

August 1, 2012
The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells.

Recommended for you

Researchers describe mechanism that underlies age-associated bone loss

September 22, 2017
A major health problem in older people is age-associated osteoporosis—the thinning of bone and the loss of bone density that increases the risk of fractures. Often this is accompanied by an increase in fat cells in the ...

Researchers develop treatment to reduce rate of cleft palate relapse complication

September 22, 2017
Young people with cleft palate may one day face fewer painful surgeries and spend less time undergoing uncomfortable orthodontic treatments thanks to a new therapy developed by researchers from the UCLA School of Dentistry. ...

Exosomes are the missing link to insulin resistance in diabetes

September 21, 2017
Chronic tissue inflammation resulting from obesity is an underlying cause of insulin resistance and type 2 diabetes. But the mechanism by which this occurs has remained cloaked, until now.

Thousands of new microbial communities identified in human body

September 20, 2017
A new study of the human microbiome—the trillions of microbial organisms that live on and within our bodies—has analyzed thousands of new measurements of microbial communities from the gut, skin, mouth, and vaginal microbiome, ...

Study finds immune system is critical to regeneration

September 20, 2017
The answer to regenerative medicine's most compelling question—why some organisms can regenerate major body parts such as hearts and limbs while others, such as humans, cannot—may lie with the body's innate immune system, ...

Immune cells produce wound healing factor, could lead to new IBD treatment

September 20, 2017
Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.